Entheon Biomedical Corp. (ENBI.CN)
CAD 0.1
(-16.67%)
CAD 0.1
(-16.67%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -300 Thousand CAD | 95.73% |
| 2022 | -7.03 Million CAD | 18.89% |
| 2021 | -8.66 Million CAD | -98.03% |
| 2020 | -4.37 Million CAD | -556.11% |
| 2019 | -667.26 Thousand CAD | -323.57% |
| 2018 | -157.53 Thousand CAD | -8.66% |
| 2017 | -144.98 Thousand CAD | -7698.87% |
| 2016 | -1859.00 CAD | 79.02% |
| 2015 | -8862.00 CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -94.56 Thousand CAD | -26.32% |
| 2024 Q1 | -74.85 Thousand CAD | -1.76% |
| 2024 Q3 | -64.7 Thousand CAD | 31.58% |
| 2023 Q4 | -73.56 Thousand CAD | 22.45% |
| 2023 FY | -300 Thousand CAD | 95.73% |
| 2023 Q1 | -67.96 Thousand CAD | 98.83% |
| 2023 Q3 | -94.85 Thousand CAD | -163.55% |
| 2023 Q2 | -35.99 Thousand CAD | 47.04% |
| 2022 Q4 | -5.81 Million CAD | -429.58% |
| 2022 FY | -7.03 Million CAD | 18.89% |
| 2022 Q3 | 1.76 Million CAD | 263.7% |
| 2022 Q2 | -1.07 Million CAD | 43.49% |
| 2022 Q1 | -1.9 Million CAD | -1.93% |
| 2021 Q1 | -2.88 Million CAD | 12.36% |
| 2021 Q2 | -2.41 Million CAD | 16.29% |
| 2021 Q3 | -1.71 Million CAD | 28.78% |
| 2021 Q4 | -1.86 Million CAD | -8.76% |
| 2021 FY | -8.66 Million CAD | -98.03% |
| 2020 Q2 | -36.03 Thousand CAD | -0.42% |
| 2020 FY | -4.37 Million CAD | -556.11% |
| 2020 Q4 | -3.29 Million CAD | -2819.97% |
| 2020 Q3 | -112.68 Thousand CAD | -212.76% |
| 2020 Q1 | -35.88 Thousand CAD | 27.26% |
| 2019 Q4 | -49.32 Thousand CAD | -173.03% |
| 2019 Q3 | -18.06 Thousand CAD | 58.48% |
| 2019 Q2 | -43.51 Thousand CAD | 45.42% |
| 2019 FY | -667.26 Thousand CAD | -323.57% |
| 2019 Q1 | -79.71 Thousand CAD | -36.04% |
| 2018 Q1 | -63 Thousand CAD | -13.72% |
| 2018 FY | -157.53 Thousand CAD | -8.66% |
| 2018 Q4 | -58.6 Thousand CAD | -60.07% |
| 2018 Q3 | -36.6 Thousand CAD | -310.48% |
| 2018 Q2 | 17.39 Thousand CAD | 127.61% |
| 2017 Q2 | 1339.00 CAD | 0.0% |
| 2017 Q3 | -27.92 Thousand CAD | -2185.14% |
| 2017 Q4 | -55.39 Thousand CAD | -98.42% |
| 2017 FY | -144.98 Thousand CAD | -7698.87% |
| 2016 FY | -1859.00 CAD | 79.02% |
| 2015 FY | -8862.00 CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | -6.78 Million CAD | 95.576% |
| Asep Medical Holdings Inc | -8.22 Million CAD | 96.354% |
| BetterLife Pharma Inc. | -2.88 Million CAD | 89.616% |
| BioVaxys Technology Corp. | -7.68 Million CAD | 96.097% |
| ChitogenX Inc. | -1.55 Million CAD | 80.695% |
| Rapid Dose Therapeutics Corp. | -4.3 Million CAD | 93.034% |
| Defence Therapeutics Inc. | -13.19 Million CAD | 97.726% |
| Gemina Laboratories Ltd. | -5.21 Million CAD | 94.249% |
| Glow Lifetech Corp. | -1.64 Million CAD | 81.77% |
| Lexston Life Sciences Corp. | -867.71 Thousand CAD | 65.426% |
| Pharmala Biotech Holdings Inc. | -779.81 Thousand CAD | 61.529% |
| Doseology Sciences Inc. | -339.84 Thousand CAD | 11.725% |
| MYND Life Sciences Inc. | -1.51 Million CAD | 80.235% |
| Nova Mentis Life Science Corp. | -1.22 Million CAD | 75.499% |
| PharmaTher Holdings Ltd. | -3.11 Million CAD | 90.37% |
| PreveCeutical Medical Inc. | -1.27 Million CAD | 76.461% |
| Telescope Innovations Corp. | -5.72 Million CAD | 94.762% |